2022
Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: A CA-IBD Cohort Study
Singh S, Kim J, Luo J, Paul P, Rudrapatna V, Park S, Zheng K, Syal G, Ha C, Fleshner P, McGovern D, Sauk J, Limketkai B, Dulai P, Boland B, Eisenstein S, Ramamoorthy S, Melmed G, Mahadevan U, Sandborn W, Ohno-Machado L. Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: A CA-IBD Cohort Study. Clinical Gastroenterology And Hepatology 2022, 21: 2359-2369.e5. PMID: 36343846, DOI: 10.1016/j.cgh.2022.10.029.Peer-Reviewed Original ResearchConceptsTNF-α antagonistsRisk of hospitalizationUstekinumab-treated patientsCrohn's diseaseSerious infectionsLower riskMulticenter cohortInflammatory bowel disease-related surgeryTumor necrosis factor α antagonistsNecrosis factor α antagonistsDisease-related surgeryHigher comorbidity burdenVedolizumab-treated patientsNew biologic agentsPropensity-score matchingComorbidity burdenCause hospitalizationAdult patientsBiologic therapyCohort studyPrior hospitalizationBiologic agentsΑ antagonistsBiologic classesComparative safetyEffect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study
Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk J, Park S, Parekh N, Zheng K, Rudrapatna V, Syal G, Ha C, McGovern D, Melmed G, Fleshner P, Eisenstein S, Ramamoorthy S, Dulai P, Boland B, Grunvald E, Mahadevan U, Ohno-Machado L, Sandborn W, Singh S. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. The American Journal Of Gastroenterology 2022, 117: 1639-1647. PMID: 35973139, DOI: 10.14309/ajg.0000000000001855.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBiologic-treated patientsRisk of hospitalizationBody mass indexNormal body mass indexSerious infectionsBiologic agentsBowel diseaseCox proportional hazards analysisWorld Health Organization classificationEffect of obesityProportional hazards analysisElectronic health recordsCause hospitalizationVisceral obesityAdult patientsBaseline demographicsBiologic initiationBiologic therapyCohort studyEndoscopic outcomesMass indexOrganization classificationTreatment characteristicsStratified analysisEffectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study
Nguyen N, Luo J, Paul P, Kim J, Syal G, Ha C, Rudrapatna V, Park S, Parekh N, Zheng K, Sauk J, Limketkai B, Fleshner P, Eisenstein S, Ramamoorthy S, Melmed G, Dulai P, Boland B, Mahadevan U, Sandborn W, Ohno-Machado L, McGovern D, Singh S. Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Clinical Gastroenterology And Hepatology 2022, 21: 173-181.e5. PMID: 35644340, PMCID: PMC9701245, DOI: 10.1016/j.cgh.2022.05.008.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseNon-Hispanic patientsBiologic-treated patientsHispanic patientsSerious infectionsBiologic therapyBowel diseasePropensity score-matched cohortBurden of inflammationRisk of hospitalizationHigh ratePropensity-score matchingCause hospitalizationAdult patientsBiologic initiationCohort studyBiologic agentsMedication useHigh burdenHigh riskHospitalizationPatientsSurvival analysisSurgeryAbstractText
2015
Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study
Shatzel J, Dulai P, Harbin D, Cheung H, Reid T, Kim J, James S, Khine H, Batman S, Whyman J, Dickson R, Ornstein D. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study. Journal Of Thrombosis And Haemostasis 2015, 13: 1245-1253. PMID: 25955079, PMCID: PMC6658183, DOI: 10.1111/jth.13000.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedAnticoagulantsDrug Administration ScheduleFemaleGastrointestinal HemorrhageHeparin, Low-Molecular-WeightHospitalizationHumansLength of StayLiver CirrhosisMaleMiddle AgedNew HampshireOdds RatioRetrospective StudiesRisk FactorsTertiary Care CentersTime FactorsTreatment OutcomeVenous ThromboembolismConceptsLow molecular weight heparinHospital bleeding eventsRetrospective cohort studyMolecular weight heparinVTE prophylaxisVenous thromboembolismBleeding eventsPharmacological thromboprophylaxisCirrhotic patientsCohort studyUnfractionated heparinWeight heparinSingle-center retrospective cohort studyEnd-stage liver disease (MELD) scoreAcademic tertiary care referral centerRate of VTETertiary care referral centerRisk of VTEGastrointestinal bleeding eventsHospitalized cirrhotic patientsNew VTE eventsPharmacological VTE prophylaxisLiver Disease scoreHospital bleedingVTE events
2010
Positive predictive value of CT urography in the evaluation of upper tract urothelial cancer.
Sadow C, Wheeler S, Kim J, Ohno-Machado L, Silverman S. Positive predictive value of CT urography in the evaluation of upper tract urothelial cancer. American Journal Of Roentgenology 2010, 195: w337-43. PMID: 20966298, DOI: 10.2214/ajr.09.4147.Peer-Reviewed Original ResearchConceptsUpper tract urothelial cancerPositive predictive valueUrothelial cancerUrine cytologyCT urographyPredictive valueUrographic examinationUrothelial thickeningExact testUpper tract urothelial malignanciesMultivariate logistic regression analysisPositive urine cytologyRecords of patientsSignificant univariate predictorsLogistic regression analysisFisher's exact testT-testStudent's t-testEffect of ageFollowup imagingRetrospective reviewPathologic examinationUrothelial malignancyUnivariate predictorsMimic cancerElectronic laboratory system reduces errors in National Tuberculosis Program: a cluster randomized controlled trial.
Blaya J, Shin S, Yale G, Suarez C, Asencios L, Contreras C, Rodriguez P, Kim J, Cegielski P, Fraser H. Electronic laboratory system reduces errors in National Tuberculosis Program: a cluster randomized controlled trial. The International Journal Of Tuberculosis And Lung Disease 2010, 14: 1009-15. PMID: 20626946, PMCID: PMC8324019.Peer-Reviewed Original ResearchConceptsControl health centersHealth centersE-ChasquiIntervention health centersNational Tuberculosis ProgrammeLaboratory information systemDrug susceptibility testTuberculosis careTuberculosis ProgrammeSusceptibility testsContinuous quality improvementBaseline dataMonthsInterventionFurther dataTrialsLaboratory resultsElectronic laboratory systemError reportsClinical usersSame monthWeeksCare